PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement Meeting Abstract
| Authors: | Abou-Alfa, G.; Borbath, I.; Goyal, L.; Lamarca, A.; Macarulla, T.; Oh, D.; Roychowdhury, S.; Sadeghi, S.; Shroff, R.; Soto, J.; Pedrioli, G.; Fumagalli, L.; Dambkowski, C.; Javle, M. |
| Abstract Title: | PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement |
| Meeting Title: | ESMO 24th World Congress on Gastrointestinal Cancer 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2022 Jun 29-Jul 2 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-06-01 |
| Start Page: | S251 |
| End Page: | S252 |
| Language: | English |
| ACCESSION: | WOS:000823826500030 |
| DOI: | 10.1016/j.annonc.2022.04.107 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-16 -- Source: Wos |
